|
Synonyms: CDP7766 | UCB-4144 | UCB4144 | VR-942
Compound class:
Antibody
Comment: Abrezekimab (UCB4144) is an anti-IL-13 agent that is in development as an anti-asthmatic agent. Peptide sequences submitted to the WHO for the INN abrezekimab, match sequences claimed in UCB Pharma patent US8691233, namely sequence IDs 35 and 27 of the preferred antibody named Ab652 in the patent submission [2]. This biologic has been designed as a high-affinity antibody fragment that suitable for inhalation, to provide a more rapid onset of action at lower doses than subcutaneous systemic administration [1]. Efficacy has been demonstrated in asthma.
|
| No information available. |
Summary of Clinical Use  |
| UCB4144 (as research code VR942) has completed Phase 1 clinical trial in healthy subjects and patients with mild asthma. Positive results are reported in an abstract presented at the American Thoracic Society International Conference in Washington DC in 2017 (Abstract 4681), but these results have not been formally published in a peer-reviewed article. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02473939 | An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma | Phase 1 Interventional | Vectura Limited | This study confirmed target (IL-13) engagement in the airways of asthmatic participants who were administered inhaled doses the drug. | 1 |
